Filoviridae infectious disease

This early-stage trial is testing an experimental mRNA vaccine called mRNA-1469 to see if it is safe and can trigger an immune response against Ebola-Bundibugyo virus disease. Healthy adults aged 18 to 65 will receive either the vaccine or a placebo. The study focuses on safety a…

This early-stage study tests a new vaccine designed to prevent Sudan virus disease, a severe illness similar to Ebola. About 112 healthy adults aged 18-50 will receive either the vaccine or a placebo to check for side effects and measure immune responses. The goal is to see if th…

This early-stage trial tests a new vaccine (rVSVΔG-MARV-GP) to see if it is safe and triggers an immune response against Marburg virus, a rare but severe disease. About 112 healthy adults aged 18-50 will receive either the vaccine or a placebo. The study focuses on side effects a…

This study tests whether specially grown donor immune cells (viral-specific T-cells) can safely treat viral infections that often occur after a stem cell transplant. These infections can be serious and sometimes don't respond to standard antiviral drugs. The approach aims to boos…

This study tests whether giving patients donor-derived immune cells (VSTs) on a regular schedule can prevent dangerous viral infections after a stem cell transplant. 180 participants will be randomly assigned to receive VSTs either on a fixed schedule or only when a virus is dete…

This program provides emergency access to REGN-EB3, a combination of three antibodies, for people with confirmed Ebola virus disease. It is available to both adults and children in Ebola-affected regions, including pregnant women. The goal is to offer a potential treatment option…